Rhumbline Advisers trimmed its position in Simulations Plus, Inc. (NASDAQ:SLP) by 2.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,273 shares of the technology company’s stock after selling 1,439 shares during the period. Rhumbline Advisers owned approximately 0.25% of Simulations Plus worth $3,116,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Vantage Consulting Group Inc acquired a new stake in shares of Simulations Plus in the 4th quarter valued at approximately $53,000. Abundance Wealth Counselors acquired a new stake in Simulations Plus during the 1st quarter worth approximately $105,000. US Bancorp DE raised its holdings in Simulations Plus by 41.0% during the 4th quarter. US Bancorp DE now owns 1,317 shares of the technology company’s stock worth $95,000 after buying an additional 383 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Simulations Plus by 20.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,356 shares of the technology company’s stock worth $169,000 after buying an additional 400 shares during the period. Finally, United Capital Financial Advisers LLC acquired a new stake in Simulations Plus during the 4th quarter worth approximately $207,000. Institutional investors and hedge funds own 66.42% of the company’s stock.
In related news, Director Walter S. Woltosz sold 24,000 shares of the firm’s stock in a transaction on Monday, April 26th. The shares were sold at an average price of $68.54, for a total value of $1,644,960.00. Following the completion of the transaction, the director now directly owns 4,519,478 shares of the company’s stock, valued at $309,765,022.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Walter S. Woltosz sold 13,825 shares of the firm’s stock in a transaction on Monday, May 24th. The shares were sold at an average price of $52.18, for a total transaction of $721,388.50. Following the completion of the transaction, the director now directly owns 4,494,071 shares of the company’s stock, valued at $234,500,624.78. The disclosure for this sale can be found here. Insiders sold 61,825 shares of company stock valued at $3,807,309 over the last three months. 23.24% of the stock is owned by company insiders.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Sunday, April 11th. The technology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $13.15 million during the quarter, compared to analysts’ expectations of $12.93 million. Simulations Plus had a net margin of 23.67% and a return on equity of 9.00%. Analysts anticipate that Simulations Plus, Inc. will post 0.54 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Monday, April 26th were paid a dividend of $0.06 per share. The ex-dividend date was Friday, April 23rd. This represents a $0.24 annualized dividend and a dividend yield of 0.45%. Simulations Plus’s dividend payout ratio is currently 42.86%.
Several analysts have commented on SLP shares. Craig Hallum dropped their target price on shares of Simulations Plus from $81.00 to $74.00 and set a “hold” rating on the stock in a report on Tuesday, April 13th. Zacks Investment Research downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Friday, April 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $80.20.
Simulations Plus Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
See Also: Gap Up Stocks
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.